STMN1 (Phospho-Ser62) Antibody
- Known as:
- STMN1 (Phospho-Ser62) Antibody
- Catalog number:
- 11722
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- STMN1 (Phospho-Ser62) Antibody
Related genes to: STMN1 (Phospho-Ser62) Antibody
- Gene:
- STMN1 NIH gene
- Name:
- stathmin 1
- Previous symbol:
- LAP18, C1orf215
- Synonyms:
- SMN, OP18, PR22, PP19, PP17, Lag, FLJ32206
- Chromosome:
- 1p36.11
- Locus Type:
- gene with protein product
- Date approved:
- 1990-12-17
- Date modifiied:
- 2014-11-19
Related products to: STMN1 (Phospho-Ser62) Antibody
Related articles to: STMN1 (Phospho-Ser62) Antibody
- Stathmin 1 (STMN1) is a cytosolic phosphoprotein involved in microtubule dynamics, mitotic progression and cytoskeleton-dependent cellular behaviour. In multiple human malignancies, dysregulated STMN1 expression has been associated with aggressive clinicopathological features, adverse outcomes and, in selected settings, potential therapeutic vulnerability. Its significance in neuroendocrine neoplasms (NENs), however, has not been critically synthesised across anatomical sites. This narrative review examined the available literature on STMN1 in NENs across pulmonary, gastroenteropancreatic, adrenal, cutaneous, pituitary and thyroid settings, with the specific aim of mapping site-specific expression patterns and appraising whether reported associations with aggressive clinicopathological features were descriptive, independently validated, or functionally supported. A literature search was conducted in PubMed, Web of Science, and Scopus from inception to 25 January 2026. Twelve original studies met the inclusion criteria and were narratively synthesised. The available evidence indicates that STMN1 is not a uniform marker of neuroendocrine differentiation across tumour types, but rather a context-dependent signal more often associated with proliferative activity, high-grade morphology and malignant behaviour. The strongest evidence currently derives from pulmonary neuroendocrine neoplasms, where STMN1 has shown diagnostic utility in tissue and bronchoalveolar lavage and where preclinical targeting data are available. Outside the lung, however, the literature is limited and methodologically heterogeneous, and the evidentiary weight varies from descriptive expression studies to functional preclinical observations. Overall, STMN1 emerges as a recurrent molecular signal in several NEN settings, particularly in aggressive and high-grade disease contexts. Its causal biological relevance and clinical value, including potential implications for treatment sensitivity and tumour dissemination, remain to be demonstrated in studies specifically designed for prognostic and therapeutic validation. Current therapeutic evidence remains preclinical and should be regarded as hypothesis-generating rather than clinically actionable. - Source: PubMed
Publication date: 2026/08/06
La Salvia AnnaTanca AlessandroGaudenzi GermanoPecora GiuliaFaggiano AntongiulioVitale GiovanniCossu-Rocca PaoloFanciulli Giuseppe - The prognostic role of STMN1 and its regulatory effects on the tumor microenvironment (TME) in biliary tract cancer (BTC) remain poorly defined. This study aimed to investigate the prognostic value of STMN1 and its predictive capacity for chemotherapy and immunotherapy responses among patients with BTC. - Source: PubMed
Publication date: 2026/07/20
Wang ChangchengNan LingxiMeng QingyangLu ChengjiaCui WenkaiSuo TaoZhang ShulongLiu HoubaoWang YueqiQiu WenqingBo Xiaobo - Multiple myeloma (MM) is a heterogeneous hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow, with distinct subtypes including smoldering MM (SMM), newly diagnosed MM (NDMM), and relapsed/refractory MM (RRMM). Despite therapeutic advances, outcomes remain unsatisfactory, especially for RRMM, due to unclear heterogeneity, progression mechanisms, and crosstalk between tumor cells and the bone marrow microenvironment (BMME) via direct interactions or extracellular vesicles (EVs). - Source: PubMed
Publication date: 2026/07/15
Fan LuZhao HanCong MengyaZhang MengxiaoRouzi TuerxunayiXie BeibeiDai JifeiBao Weiying - Natural killer (NK) cells, as an integral component of the innate immune system, assume a pivotal role in combating viral infections. Our understanding of how human immunodeficiency virus (HIV) infection affects NK cell heterogeneity remains limited. - Source: PubMed
Publication date: 2026/07/20
Cao Wen-JingYang Bao-PengChen Si-YuanZhen ChengLi Xue-MengCao Xiang-YiWan Lin-YuZhang Li-PingZhang MengyuanGao Jia-MinZhang ChaoJiao Yan-MeiFan XingXu Ruo-NanHuang Hui-HuangWang Fu-ShengSong Jin-Wen - This study aimed to explore the intra- and inter-tumoral heterogeneity, gene expression profiles, tumor microenvironment (TME) alterations and the potential of therapeutic marker discovery in endometrial cancer (EC). - Source: PubMed
Publication date: 2026/07/15
Zhong ShanliangLiu JianyaoXu HanziLv JuanLi HuixinHu HuanhuanXiao ShuyueXie XinyiLi YueWu YinanWu WangfeiGong Zhen